|Bid||72.00 x 200|
|Ask||73.30 x 100|
|Day's Range||70.30 - 74.70|
|52 Week Range||28.35 - 136.90|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Examining Puma Biotechnology Inc’s (NASDAQ:PBYI) past track record of performance is a valuable exercise for investors. It enables us to understand whether the company has met or exceed expectations, whichRead More...
Puma (PBYI) posts narrower-than-expected loss in Q4. Revenues also surpass estimates supported by sales of the company's only marketed drug, Nerlynx.
The Los Angeles-based company said it had a loss of $1.71 per share. Losses, adjusted for stock option expense, were $1.03 per share. The results topped Wall Street expectations. The average estimate of ...
KemPharm, Inc. (NASDAQ:KMPH) ran into the end of last week on news related to the company’s lead development program. At the close of trade on Friday, KemPharm shares were going for around six dollars apiece, up more than 13% on the day’s open. Premarket on Monday, shares rose again to $6.35 but have since settled […] The post Here’s What’s Moving KemPharm And Puma Biotechnology appeared first on Market Exclusive.
Puma (PBYI) enters an exclusive agreement with CANbridge under which the latter will seek regulatory approval for Nerlynx in China and develop and commercialize it in the region.
Puma's licensing agreement for breast cancer drug Nerlynx won't inhibit takeover interest for Puma, an analyst said Tuesday.
Investors need to pay close attention to Puma Biotechnology (PBYI) stock based on the movements in the options market lately.
Short interest is moderate for PBYI with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ETFs that hold PBYI had net inflows of $286 million over the last one-month.
In case you missed it, here are some of Benzinga's top stories from Wednesday, Jan. 24, 2018. A Pharma Trade From Goldman Jayson Derrick outlines a bull and bear call on Catelent, Inc (NYSE: CTLT ) and ...
Puma's (PBYI) shares decline after CHMP conveyed the company that the former will probably vote against the approval of breast cancer drug Nerlynx at the CHMP meeting scheduled in February.
Puma Biotechnology’s shares are getting pounded today after its breast cancer drug neratinib suffered a regulatory setback that makes a 2018 European launch unlikely. One analyst says the news “makes the M&A narrative more challenging.”
Puma Biotechnology Inc (NASDAQ:PBYI) is down 27% in early trading Wednesday after announcing a disappointing outcome from a meeting with European regulators over its breast cancer drug neratinib. The biotech met with regulators at the European Medicines Agency (EMA) to go over outstanding issues with the marketing application for neratinib, but failed to convince them that the drug is approvable. CHMP indicated that, in its opinion, the benefit risk assessment is negative as the study results are based on evidence from a single pivotal trial and the 2- and 5-year invasive disease free survival (iDFS) benefits observed to-date may lack sufficient clinical relevance.
Puma Biotechnology Inc (NASDAQ: PBYI ) could face a setback in the launch of its breast cancer drug neratinib, as the European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, ...
Amarin Corporation plc (NASDAQ:AMRN) and Puma Biotechnology, Inc. (NASDAQ:PBYI) both updated markets as to the progress of their respective lead development programs early this week and both fresh inputs have translated to movement in the companies’ share prices. Here’s what happened. Amarin Amarin is trying to get an asset called Vascepa to market in the […] The post Here’s What’s Moving Amarin Corporation and Puma Biotechnology appeared first on Market Exclusive.
Puma Biotechnology Inc. shares dropped 26.7% in premarket trade on Wednesday after the company said a European Medicines Agency committee completed a negative vote for its breast cancer therapy neratinib, ...
Puma Biotechnology Inc. shares fell Tuesday after the biotech company said it will likely not get a positive result on its European marketing application for a breast cancer treatment. Puma Biotechnology ...
Puma's (PBYI) shares jump in a year's time on its cancer drug Nerlynx's approval in the United States coupled with strategic collaborations.
Aradigm Corporation (NASDAQ:ARDM) and Puma Biotechnology, Inc. (NASDAQ:PBYI) both served up key updates in the biotechnology space this week, with each relating to a respective in-house development program. Here’s what happened with each company and what comes next for both. Aradigm Aradigm announced on Thursday that the FDA Antimicrobial Drugs Advisory Committee did not recommend […] The post Biotech Updates: Aradigm Corporation & Puma Biotechnology appeared first on Market Exclusive.